Provider Memorandum

May 2023

RE: FDA Withdraws coverage for **hydroxyprogesterone** caproate, (makena)

Dear Provider,

Molina Healthcare of Nevada will follow the FDA decision to discontinue coverage for J1726, effective 4/7/2023. Providers should be aware that the manufacturer has recalled this injectable.

Reference Press Release (April 6, 2023)

Visit: https://www.fda.gov/news-events/press-announcements/fda-commissioner-and-chief-scientist-announce-decision-withdraw-approval-makena

Today, the U.S. Food and Drug Administration announced the final decision to withdraw approval of Makena—a drug that had been approved under the accelerated approval pathway. This drug was approved to reduce the risk of preterm birth in women pregnant with one baby who have a history of spontaneous preterm birth. The decision was issued jointly by the FDA Commissioner and Chief Scientist. Effective today, Makena and its generics are no longer approved and cannot lawfully be distributed in interstate commerce.

Thank You for your continued partnership with Molina Healthcare of Nevada

Sincerely,

Molina Healthcare of Nevada,
Provider Services